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BACKGROUND & AIMS: The risk of esophageal adenocarcinoma (EAC) in patients with non-dysplastic Barrett’s
esophagus (NDBE) is low, so there is debate over the role of ongoing surveillance for patients
with NDBE. It is important to identify patients at low risk for progression. We assessed cancer
risk based on the subsequent number of endoscopies showing persistence of NDBE in a
nationwide study in the Netherlands.
METHODS: In a population-based study, patients with a ﬁrst diagnosis of NDBE were selected from the
Dutch nationwide registry of histopathology. We calculated incidence rates and incidence rate
ratios (IRR) for high-grade dysplasia (HGD) and EAC to determine whether the number of
endoscopies negative for dysplasia and the persistence of NDBE over time associate with pro-
gression to malignancy.
RESULTS: We identiﬁed 12,728 patients with NDBE during 2003 and 2013. HGD or EAC developed in 436
patients (3.4%) during 64,537 person-years of follow up (median, 4.9 years). The rate of
progression to HGD or EAC was 0.68 (95% CI, 0.61–0.74) per 100 person-years. In patients with
2 consecutive endoscopies showing NDBE, the rate of progression to HGD or EAC decreased to
0.55 (95% CI, 0.46–0.64) per 100 person-years (IRR 0.72; 95% CI, 0.60–0.87). Overall, the
incidence of HGD or EAC decreased by 14% for each year of progression-free follow-up (IRR,
0.86; 95% CI, 0.81–0.92).
CONCLUSION: In a population-based study in the Netherlands, we found patients with stable NDBE to have a
low risk of progression to HGD or EAC. These ﬁndings indicate that surveillance intervals might
be lengthened or even discontinued in subgroups patients with persistent NDBE.
Keywords: PALGA; Prognostic Factor; Biomarker; Risk Factor; Epidemiology.
Barrett’s esophagus (BE) is a premalignant condi-tion, in which the normal squamous epithelium
of the distal esophagus is replaced by columnar or in-
testinal epithelium containing goblet cells.1 BE is
considered to be the predominant precursor lesion of
esophageal adenocarcinoma (EAC). The progression
from BE to EAC occurs through consecutive histological
stages of increasing grades of epithelial dysplasia, from
intestinal metaplasia without dysplasia to low-grade
dysplasia (LGD), high-grade dysplasia (HGD), and ﬁnally
EAC.2
In the Western world, the incidence of BE and EAC is
increasing.3 Because EAC is frequently detected in an
advanced stage, patients with EAC have a poor prognosis,
with a 5-year survival following a diagnosis of EAC of
<20%.4 To detect HGD and EAC at an early stage and
hence prevent further progression to invasive EAC,
endoscopic surveillance with biopsy sampling every 3–5
years is recommended in patients with nondysplastic BE
(NDBE).5,6
However, as the efﬁcacy of surveillance on reducing
mortality of patients with BE compared with the general
population is unclear, the value of ongoing surveillance
Abbreviations used in this paper: BE, Barrett’s esophagus; CI, conﬁdence
interval; EAC, esophageal adenocarcinoma; HGD, high-grade dysplasia;
IR, incidence rate; IRR, incidence rate ratio; IQR, interquartile range; LGD,
low-grade dysplasia; NDBE, nondysplastic Barrett’s esophagus; ROC,
receiver-operating characteristic.
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for patients with NDBE is debated.7,8 In addition, as the
absolute risk of malignant progression in patients with
NDBE is low (<0.5%/year), the majority of patients
with NDBE will never progress beyond NDBE or LGD
and will only experience the disadvantages of the sur-
veillance program.9,10 Therefore, it would be helpful to
identify patients at low risk of malignant progression, as
in these patients surveillance intervals might be
lengthened or even discontinued. There is conﬂicting
evidence whether persistence of NDBE over time is
associated with a decreased risk of malignant
progression.11–13
The aim of this study was to assess the risk of ma-
lignant progression associated with the number of
consecutive endoscopies showing NDBE and the persis-
tence of NDBE over time in a nationwide cohort of pa-
tients with NDBE.
Methods
For this cohort study, we searched PALGA, the
nationwide registry of histopathology and cytopathology,
with approval of their Review Board to identify all pa-
tients with BE in the Netherlands. Since 1991, PALGA has
complete national coverage, including all pathology lab-
oratories from all academic and nonacademic hospitals
in the Netherlands.14 All reports in the database are
registered as written summaries of conclusions of the
original pathology report combined with diagnostic
codes in line with the SNOMED (Systematised Nomen-
clature of Medicine) classiﬁcation of the College of
American Pathologists.15 For each report, gender, age,
date of pathology examination, summary text, and diag-
nostic codes are available.
Data Collection
Pathology reports between January 2003 and
December 2012 were reviewed to identify all adult pa-
tients in the Netherlands who underwent endoscopic
biopsy and got a new diagnosis of BE. BE was deﬁned as
the presence of metaplastic epithelium with goblet cells
in esophageal biopsies. The search was performed with
the following diagnostic codes, a combination of esoph-
agus and intestinal metaplasia or Barrett’s metaplasia.
For detailed information, see Supplementary Table 1.
The following exclusion criteria were used: a previous or
synchronous diagnosis of atypia, dysplasia or EAC at
initial diagnosis, histological follow-up <1 year, or
development of an adenocarcinoma distal to the gastric
cardia or other gastric malignancies. Furthermore, to
avoid underestimating of the malignant progression rate,
all summary texts of the pathology reports, coded as
“Barrett’s metaplasia,” were manually reviewed to
exclude cases without intestinal metaplasia.16 Pathology
reports coded as esophageal malignancy were reviewed
to exclude patients who developed other histological
subtypes of esophageal cancer. To avoid an effect of the
(nondetected) co-presence of dysplasia in the set of bi-
opsies during initial NDBE diagnosis, patients with a
diagnosis of dysplasia or EAC within the ﬁrst year after
initial diagnosis were excluded from the primary
analysis.
For each patient admitted to the cohort, all pathology
reports from 1991 to the end of the study period (May
2016) related to the esophagus were collected. Diag-
nostic codes and synonyms for indeﬁnite for dysplasia,
LGD, HGD, and EAC were identiﬁed by manually exam-
ining a random sample of 200 reports in the database,
after which all other reports were automatically
searched for these identiﬁed terms. Complete pathology
reports (including clinical data and macroscopic and
microscopic ﬁndings) were retrieved for all patients with
dysplasia or EAC during follow-up to document whether
another pathologist conﬁrmed the diagnosis. Where
present, the pathology reports of surgical and endoscopic
resection specimens were evaluated to verify the loca-
tion of the tumor. For each surveillance endoscopy, the
ﬁnal diagnosis was deﬁned as the highest grade of
dysplasia in the same set of biopsies. Since a repeat
endoscopy is frequently performed within 3 months in
patients with esophagitis, and review by 2 pathologists is
warranted for patients with dysplasia of any grade, a
pathology report within 3 months was not considered to
be a surveillance endoscopy. Therefore, for each pa-
thology report the diagnosis was deﬁned as the highest
grade of dysplasia during the 3-month period after that
report in case of an endoscopy performed within 3
months, and as agreement after revision when the pa-
thology slides have been reviewed by a second
pathologist.
What You Need to Know
Background
Surveillance of patients with nondysplastic Barrett’s
esophagus (NDBE) has multiple limitations—we
might increase the effectiveness of surveillance by
identifying patients at low risk for progression.
Findings
In a large cohort of patients with NDBE, the risk of
progression to malignancy was 0.68 per 100 person-
years. This risk decreased signiﬁcantly in patients
with at least 2 consecutive endoscopies showing
NDBE.
Implications for patient care
Stable persistence of NDBE can be used as an indi-
cator of lower risk of progression. Patients with
multiple negative ﬁndings from endoscopy might not
beneﬁt from routine surveillance, so surveillance
could be discontinued at an earlier endpoint than
currently recommended.
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Veriﬁcation Cohort
In the total study cohort, diagnosing BE required only
the histological presence of intestinal metaplasia. How-
ever, to diagnose BE, columnar epithelium has to be
located at least 1 cm proximal to the gastric folds.5,6 To
verify the diagnosis of BE, we compiled a veriﬁcation
cohort. This cohort consisted of the part of the total
cohort that had at least 1 biopsy evaluated at the Rad-
boud University Medical Center in Nijmegen. Subse-
quently, we collected corresponding endoscopic data and
length of the BE segment to assess the rate of mis-
diagnoses of NDBE (ie, length of the BE segment <1 cm).
Data Analysis
Endpoints were development of EAC, or the combined
endpoint of HGD and EAC, occurring at least 12 months
after an initial biopsy showing presence of NDBE.
Dysplasia occurring in squamous epithelium was not
included as an outcome.
For each patient, incidence rates (IRs) with 95%
conﬁdence interval (CIs) for progression to EAC, or HGD
EAC, were calculated as the number of events divided by
person-years of follow-up and were expressed as events
per 100 person-years (%/year) of follow-up. Follow-up
time was considered as time elapsed from initial NDBE
diagnosis to last follow-up endoscopy, deﬁned as EAC
diagnosis, HGD diagnosis if EAC did not occur subse-
quently, or last histopathology report in the database
(through May 2016), whichever came ﬁrst.
We assessed the effects of the number of endoscopies
showing NDBE, the persistence of NDBE over time, and
the calendar year of BE initial diagnosis (2003–2012) on
the malignant progression rates. Poisson regression was
used to compare IRs and calculate IR ratios (IRRs).17 To
account for varying periods of follow-up, log-trans-
formed person-time was included in the model as an
offset. We adjusted for sex and age at endoscopy date.
Descriptive data are presented as mean  SD or median
(interquartile range [IQR]) (when data are not normally
distributed) for continuous variables and frequency and
percentage for categorical variables. Comparisons be-
tween groups and included and excluded patients were
calculated by using Fisher exact test, Mann-Whitney
U test, or unpaired t test when appropriate. A 2-sided
P value of <.05 was considered to be statistically sig-
niﬁcant. All analyses were conducted using SPSS version
22.0 (IBM Corp, Armonk, NY).
For the analysis of malignant progression rates by the
number of consecutive endoscopies showing NDBE, we
categorized patients into 5 individual overlapping co-
horts according to the number of consecutive endos-
copies that showed NDBE. Persistent NDBE was deﬁned
as at least 2 consecutive endoscopies showing NDBE
(initial NDBE diagnosis and the ﬁrst follow-up diagnosis).
Patients who had 1, 2, 3, 4, and 5 consecutive endos-
copies, beginning with the initial endoscopy, and at least
1 ensuing surveillance endoscopy were included in
group 1, 2, 3, 4, and 5, respectively. For each group, the
duration of follow-up was calculated from the date of the
last persistent NDBE endoscopy until last histopathology
report in the database. Hence, this will indicate the ma-
lignant progression risk in the period after the last
persistent NDBE endoscopy.
To address the time-dependent component and to
include mainly endoscopies performed as part of a sur-
veillance program, additional analyses were performed
by redeﬁning the patient subgroups. We considered that
an endoscopy performed within 1 year of the preceding
endoscopy was not performed as a surveillance endos-
copy, but possibly due to for example gastrointestinal
symptoms or abnormalities at the preceding endoscopy
without pathologic conﬁrmation of neoplasia. In this
analysis, we considered the ﬁrst endoscopy showing
NDBE as initial BE diagnosis and follow-up endoscopies
as those performed at least 1 year apart. For the second,
third, fourth, and ﬁfth endoscopy to count, at least 1 year
was required as the minimum time interval between
endoscopies showing NDBE. Patients with repeat en-
doscopies <1 year of the preceding endoscopy, thus
probably not performed in the context of a surveillance
program, were analyzed separately.
To assess the impact of discontinuing surveillance after
1, 2, 3, 4, and 5 endoscopies showing NDBE and, hence, the
risk of missing HGD or EAC, we performed an analysis to
calculate the sensitivity and speciﬁcity for detecting HGD
or EAC. Numbers needed to screen,when surveillance after
up to 5 endoscopies was not stopped, were calculated us-
ing the reciprocal of the absolute risk reduction.
To assess the effect of persistent NDBE over time, we
calculated the progression-free time for each patient. The
progression-free time is deﬁned as the time from initial
NDBE diagnosis until last endoscopy showing NDBE in
patients with progression to dysplasia or EAC, or until
the penultimate endoscopy showing NDBE in patients
without progression. The area under the receiver-
operating characteristic (ROC) curve was applied to
evaluate the prognostic impact of length of progression-
free time in predicting malignant progression. Therefore,
we transformed the time-dependent endpoint (HGD or
EAC) into a binary endpoint that is clinically relevant (ie,
development of HGD or EAC within 10 years). Hence,
only patients who had a minimum of 10 years of follow-
up or who progressed to HGD or EAC within 10 years
could be included in this analysis. The cutoff value for the
risk of malignant progression was determined from the
ROC curve at the cutoff point with the most optimal
sensitivity and speciﬁcity.
Sensitivity Analysis
Persistent LGD is an indication for endoscopic treat-
ment according to current guidelines. As sensitivity
analysis, we used treated LGD and HGD or EAC devel-
opment as an outcome for malignant progression to
FLA 5.5.0 DTD  YJCGH56023_proof  23 November 2018  4:02 pm  ce OB
- 2018 Low Cancer Risk in Persistent NDBE 3
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
correct for prevented HGD or EAC by endoscopic treat-
ment. Treated LGD was deﬁned as squamous epithelium
without intestinal metaplasia or a neo-Z line on endos-
copies following at least 2 LGD diagnoses. The date of the
last LGD diagnosis before treatment was taken as the
date of malignant progression (the outcome).
In a second sensitivity analysis, we assessed the effect
of misclassiﬁcation of BE on the progression rates to-
ward HGD or EAC given the very low risk of malignant
progression in patients with BE <1 cm (Supplementary
Methods).
Results
Patients
In total, 35,161 patients with a ﬁrst histological
diagnosis of NDBE between 2003 and 2013 were iden-
tiﬁed (Figure 1). After using the exclusion criteria,
12,728 patients were included in the main analysis, who
were followed up for a maximum of 13 years. The de-
mographic features of the study population are shown in
Supplementary Table 2.
Surveillance Patterns
A total of 38,998 surveillance endoscopies were
performed within the study cohort, with a median of 3
endoscopies per patient (range, 2–16). Patients were
followed for a total of 64,537 years (median time per
patient 4.4 [IQR, 3.0–6.8] years). Median time interval
between initial endoscopy and ﬁrst follow-up endoscopy
was 2.3 (IQR, 1.8–3.2) years. Mean age at the last per-
formed endoscopy was 63  11 years.
Veriﬁcation Cohort
Our veriﬁcation cohort consisted of 218 patients with
NDBE who had undergone an upper endoscopy at the
Radboud university medical center. Of these, 197
(90.4%) patients had a BE segment 1 cm, with a me-
dian length of 3.0 (IQR, 1.0–4.3) cm. Twenty-one (9.6%)
patients only had an irregular Z line (endoscopic extent
of esophageal columnar mucosa <1 cm). Of those, none
progressed to dysplasia or EAC during follow-up
(median 2.91 years). Patients with BE <1 cm under-
went signiﬁcantly fewer endoscopies than patients with
a BE segment 1 cm (median 2 [IQR, 2–3] vs 3 [IQR,
2–4]; P ¼ .01).
Incidence of Dysplasia and EAC
Progression beyond NDBE was observed in 1654
(13%) patients. Supplementary Tables 3 and 4 show that
a substantial number of dysplasia diagnoses (65%) was
conﬁrmed by a second pathologist and that the vast
majority of detected adenocarcinomas (96%) was clearly
originating from a Barrett’s segment. During the follow-
up period (2003–2016) malignant progression was
seen in a total of 436 patients (304 EAC) (3.4%), after a
median follow-up of 4.9 (IQR, 3.1–7.3) years. This results
in an IR of EAC and the combined endpoint of HGD of
EAC of 0.47 (95% CI, 0.42–0.53) and 0.68 (95% CI,
0.61–0.74) per 100 person-years, respectively.
Persistent NDBE and Incidence of
HGD and EAC
At the ﬁrst follow-up endoscopy, 219 (1.7%) patients
with an initial diagnosis of NDBE were diagnosed with
HGD or EAC after a median of 3.4 (IQR 2.2–6.0) years.
Figure 3 demonstrates that only 61 (1.0%) patients and
22 (0.8%) progressed to HGD/EAC after 2 and 3 negative
endoscopies, respectively.
Supplementary Table 5 summarizes the characteris-
tics and progression risks across the 5 groups based on
the number of endoscopies showing NDBE. On multi-
variate Poisson regression, there was a signiﬁcantly
decreased risk of malignant progression after at least 2
or 3 endoscopies showing NDBE compared with patients
with only 1 NDBE endoscopy (adjusted IRR for 2 nega-
tive endoscopies, 0.72; 95% CI, 0.60–0.87; and adjusted
IRR for 3 negative endoscopies, 0.65; 95% CI, 0.49–0.86).
The IR did not decrease further in patients with at least 4
or 5 endoscopies showing NDBE (Figure 3).
In the subgroup of patients undergoing endoscopies
at least 1 year apart, the risk of malignant progression is
decreasing in patients with persistence of NDBE over
consecutive surveillance endoscopies (HGD or EAC
IR: 0.69, 0.50, 0.45, 0.45, and 0.22 per 100 person-years
for 1–5 negative endoscopies, respectively) (Table 1 and
Figure 3). On the contrary, the HGD or EAC IRs are
Figure 1. Flowchart of included patients. BE, Barrett’s
esophagus; EAC, esophageal adenocarcinoma; HGD, high-
grade dysplasia; IND, indeﬁnite for dysplasia; LGD, low-
grade dysplasia; NDBE, nondysplastic Barrett’s esophagus.
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increasing in patients with repeat endoscopies <1 year
(HGD or EAC IR: 0.51, 0.69, 0.71, 0.92, and 1.09 per 1000
patient-years for persistence of NDBE on 1–5 endos-
copies, respectively).
The sensitivity and speciﬁcity for detecting HGD or
EAC after discontinuing surveillance after 1, 2, 3, 4, and 5
negative endoscopies are shown in Figure 4. In our
cohort, 32 HGD or EAC cases will be missed, but 1800
patients will not undergo unnecessary surveillance en-
doscopies when surveillance is discontinued after 3
negative endoscopies.
Persistence of NDBE Over Time
Subsequently, we assessed HGD or EAC risk accord-
ing to the duration of progression-free follow-up
regardless of the number of endoscopies. The IR of HGD
or EAC decreased with approximately 14% for each year
of follow-up without progression (adjusted IRR, 0.86;
95% CI, 0.81–0.92). For the subgroup of patients with at
least 10 years of follow-up or development of HGD or
EAC within 10 years (n ¼ 1219), the association between
the number of patients developing HGD or EAC and
progression-free time as a risk stratiﬁcation tool is
shown in Figure 5A. Based on these results a ROC curve
was constructed, which showed an area under the ROC
curve of 0.86 (95% CI, 0.85–0.88; P < .001) (Figure 5B).
Therefore progression-free time can be considered a
good predictor for risk of malignant progression. A cutoff
value of 4 years of progression-free time was associated
with a sensitivity and speciﬁcity of 90.4% (95% CI,
87.1%–93.1%) and 72.4% (95% CI, 69.2%–75.5%) for
detecting HGD or EAC, respectively.
Lastly, we examined malignant progression rates ac-
cording to calendar year of BE diagnosis. We did not
observe an increasing trend in malignant progression
rates across the calendar years in the total cohort
(Supplementary Figure 1).
Sensitivity Analyses
A comparison between patients who were and who
were not included in the main study cohort is shown in
Supplementary Table 2. Patients with malignant pro-
gression within 1 year of follow-up and patients without
follow-up were signiﬁcantly older than patients in the
study cohort (67  12 and 64  14 vs 58  11.5; P <
.001).
In the sensitivity analysis including treated LGD
combined with HGD or EAC as an outcome, the number
of outcomes increased by 23 to a total of 459. This
resulted in an IR of 0.71 per 100 person-years (95% CI,
0.65–0.78; P ¼ .43).
Figure 2. Flowchart of pa-
tients with nondysplastic
Barrett’s esophagus (BE)
and their follow-up di-
agnoses. EAC, esophageal
adenocarcinoma; HGD,
high-grade dysplasia; IND,
indeﬁnite for dysplasia;
IQR, interquartile range;
LGD, low-grade dysplasia;
NDBE, nondysplastic
Barrett’s esophagus.Q4
Figure 3. Incidence rates of high-grade dysplasia (HGD) or
esophageal adenocarcinoma (EAC) among consecutive en-
doscopies showing nondysplastic Barrett’s esophagus
(NDBE) in the total cohort (left), the group of patients under-
going surveillance endoscopies at least 1 year apart (middle),
and the group of patients undergoing surveillance endos-
copies within 1 year (right).
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In a second sensitivity analysis accounting for the
possible inclusion of patients without endoscopic pres-
ence of BE, we observed that only a misclassiﬁcation rate
of more than 25% will signiﬁcantly inﬂuence the HGD or
EAC IR (IR, 0.78; 95% CI, 0.72–0.87; P ¼ .02). The
possible inclusion of patients with BE <1 cm did not
signiﬁcantly change progression rates in patients with 2
consecutive endoscopies showing NDBE (P ¼ .67)
(Supplementary Figure 2).
Discussion
In this large, population-based cohort study of 12,728
patients with NDBE, we observed that the risk of ma-
lignant progression decreased by 28% in patients with
consecutive endoscopies showing persistence of NDBE.
This risk decreases even further among more negative
endoscopies in patients with surveillance endoscopies
performed at least 1 year apart. For every year of follow-
up without progression, the risk of HGD or EAC
decreased with 14%.
Previous studies on malignant progression risk in
patients with persistent NDBE have shown variable re-
sults. The results of our study are largely consistent with
those reported in a multicenter prospective study.11 In
this study, 1401 patients were divided into 5 groups
depending on the number of endoscopies showing NDBE.
The annual risk of EAC declined progressively according
to the number of negative endoscopies (1–5), from
0.32% to 0.27%, 0.16%, 0.20%, and 0.11%, respectively.
Another study evaluated 480 patients with persistent
NDBE.13 The authors found a non–statistically signiﬁcant
decrease in the risk of progression in subjects with
multiple endoscopies showing NDBE (hazard ratio, 0.51;
95% CI, 0.11–1.81). However, in the study population,
only 16 subjects progressed to HGD or EAC, resulting in a
too-low statistical power. In contrast to our results, a
cohort study of 28,561 male BE patients showed that
the annual risk of EAC increased with each successive
Table 1.Group Characteristics and Risk of Progression to EAC and HGD or EAC Based on the Number of Consecutive
Endoscopies Showing NDBE in Patients Undergoing Surveillance Endoscopies at Least 1 Year Apart
Variable
Upper Endoscopies Showing NDBE
1 n ¼ 11,684 2 n ¼ 4888 3 n ¼ 1832 4 n ¼ 579 5 n ¼ 161
Male 7928 (67.9) 3399 (69.5) 1275 (69.6) 421 (72.7 ) 119 (73.9)
Age, y 57.9  11.5 58.8  10.7 59.7  10.3 61.1  10.2 61.2  9.9
Time to nth FU endoscopy, y 0.0 (0.0–0.0) 2.4 (1.8–3.0) 4.3 (3.8–5.2) 6.3 (5.7–7.1) 8.1 (7.3–8.7)
FU after n endoscopies, y 4.4 (3.0–6.7) 3.7 (2.8–5.9) 3.2 (2.5–5.1) 3.1 (2.4–4.1) 2.4 (2.1–3.3)
EAC
Development of EAC 280 (2.4) 65 (1.3) 18 (1.0) 5 (0.9) 1 (0.6)
EAC incidence rate/100 PY (95% CI) 0.48 (0.42–0.53) 0.30 (0.24–0.38) 0.25 (0.16–0.39) 0.25 (0.09–0.56) 0.22 (0.11–1.10)
Unadjusted incidence rate ratio (95% CI)a 1.00 (reference) 0.64 (0.48–0.83) 0.53 (0.32–0.84) 0.53 (0.22–1.29) 0.47 (0.07–1.88)
Adjusted incidence rate ratio (95% CI)a,b 1.00 (reference) 0.56 (0.43–0.73) 0.42 (0.26–0.68) 0.36 (0.15–0.87) 0.28 (0.04–1.98)
HGD/EAC
Development of HGD/EAC 407 (3.5) 108 (2.2) 32 (1.7) 9 (1.6) 1 (0.6)
HGD/EAC incidence rate/100 PY (95% CI) 0.69 (0.63–0.76) 0.50 (0.41–0.61) 0.45 (0.31–0.63) 0.45 (0.22–0.84) 0.22 (0.11–1.10)
Unadjusted incidence rate ratio (95% CI)a 1.00 (reference) 0.73 (0.59–0.90) 0.65 (0.45–0.93) 0.66 (0.34–1.28) 0.32 (0.05–2.29)
Adjusted incidence rate ratio (95% CI)a,b 1.00 (reference) 0.65 (0.52–0.80) 0.52 (0.36–0.74) 0.46 (0.24–0.88) 0.20 (0.03–1.39)
Values are n (%), mean  SD, or median (interquartile range), unless otherwise indicated.
CI, conﬁdence interval; EAC, esophageal adenocarcinoma; FU, follow-up; HGD, high-grade dysplasia; NDBE, nondysplastic Barrett’s esophagus; PY, patient-
years.
aPoisson regression used to calculate incidence rate ratio using the ﬁrst upper endoscopy as the reference group.
bPoisson model adjusted for gender and age at nth FU endoscopy.
Figure 4. Impact of discontinuing surveillance and risk of
missing high-grade dysplasia or esophageal adenocarcinoma
after 1, 2, 3, 4, and 5 endoscopies showing nondysplastic
Barrett’s esophagus expressed in sensitivity and speciﬁcity
and corresponding numbers needed to screen to detect 1
case of high-grade dysplasia or esophageal adenocarci-
noma, when not ceasing surveillance after 1, 2, 3, 4 and 5
negative endoscopies. AUC, area under the receiver-
operating curve.
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non-neoplastic endoscopy (rate ratio per additional
endoscopy, 1.43; 95% CI, 1.25–1.64).12 However, this
study assessed cancer risk in so-called non-neoplastic BE,
as the dysplasia status was unknown in the vast majority
of patients, while we assessed the risk in persistent
NDBE. Therefore, it is possible that this increased risk of
EAC was related to intense dysplasia surveillance, and
due to repeated endoscopies in patients with dysplasia.
Potential sources of bias for the observed decreasing
EAC IRs in patients with persistent NDBE could be the
increasing incidence of EAC over years or the improved
imaging techniques such as chromoendoscopy or virtual
endoscopy in more recent years.18 Therefore, we addi-
tionally assessed HGD or EAC risk according to calendar
year. No increase in the risk of HGD or EAC in more
recent years was observed, which supports that the
decreasing risk is not due to improved diagnostic yield or
changes in clinical practice.
In patients with at least 4 or 5 consecutive negative
endoscopies, the decreasing risk of malignant progres-
sion was not observed in the total cohort. Added to a
smaller sample size, we assume that the groups of pa-
tients with at least 4 or 5 negative endoscopies in the
total cohort may have undergone a selection bias by in-
clusion of a subgroup of so-called high-risk patients.
Patients with for example gastrointestinal symptoms or
(slight) endoscopic or pathologic abnormalities, thus at
highest risk for malignant progression, are likely to have
undergone endoscopies (not in the context of a surveil-
lance program) more frequently. This is supported by the
shorter time interval between endoscopies in patients
with 4 or 5 endoscopies showing NDBE. Additionally, in
patients who are more likely to follow a surveillance
program (ie, endoscopies performed at least 1 year
apart) the risk of malignant progression is decreasing
(0.69, 0.50, 0.45, 0.45, 0.22), which supports our
hypothesis.
Dysplasia is commonly missed at initial endoscopy,
due to poor adherence to biopsy protocols, sampling
error, and overlying erosive esophagitis. This supported
by the high rate of progression within 1 year after initial
diagnosis in our cohort (n ¼ 458). The decreasing inci-
dence of HGD or EAC among patients with persistent
NDBE could be due to the miss rate of prevalent
dysplasia or EAC at the time of BE diagnosis.19 With
consecutive nonprogressive endoscopies the risk of false
negative results decreases, which improves the negative
predictive value of the endoscopy. The results of this
study implicate that the risk of prevalent dysplasia or
cancer may be increased for more than 1 year after a BE
diagnosis.
Recently, an analysis of NDBE patients has suggested
that the extent of clonal diversity at baseline is a strong
predictor of progression and that this diversity will not
change over time.20 Patients with progression may
already have a high level of clonal diversity, whereas
patients with persistent NDBE have a low level of di-
versity, and hence a lower risk of progression.
Despite the growing evidence showing a low risk of
EAC in patients with NDBE, guidelines recommend life-
long surveillance every 3–5 years.5 In the current study,
the vast majority (87.0%) of patients with NDBE did not
show progression during the study period. Hence, this
group would not beneﬁt from a surveillance program
and would only experience the associated burden and
costs. As currently practiced, endoscopic surveillance has
multiple limitations and improving the effectiveness by
risk stratiﬁcation is therefore of interest. Endoscopic
treatment should be considered in patients at highest
risk for malignant progression, and less strict surveil-
lance for patients at lowest risk. Discontinuing surveil-
lance after a certain age would resemble current
colorectal surveillance strategies, where surveillance
should not be routinely continued after 75 years of age,
with individualized surveillance based on comorbidities
and ﬁndings in prior colonoscopies for patients 75–85
years of age.21 When surveillance is continued after 3
negative endoscopies, 57 patients would undergo
Figure 5. Comparison of length of progression-free time after an initial diagnosis of nondysplastic Barrett’s esophagus
between patients with and without development of (A) high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) and
(B) the corresponding receiver-operating curve curves for the 1219 patients with at least 10 years of follow-up or development
of HGD or EAC within 10 years. The vertical line and the arrow correspond to a cutoff value of 4 years. AUC, area under the
receiver-operating curve.
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unnecessary surveillance endoscopies to detect 1 patient
with HGD or EAC. Hence, results from our study imply
that in patients with multiple negative endoscopies
harms and costs may outweigh the potential beneﬁts of a
surveillance program. Surveillance may be discontinued
at an earlier endpoint than currently recommended, in
particular in patients with life-limiting comorbidity.
This study has several strengths. The study consists
of a large cohort of BE patients who had multiple follow-
up endoscopies. Due to the population-based design,
patients with NDBE of all ages, both sexes, and diagnoses
in primary, secondary, and tertiary centers were
included. In the Netherlands, health care is basically
accessible to all inhabitants, which eliminates diagnostic
bias. This study reﬂects standard clinical practice, and its
ﬁndings may be widely applicable within standard health
care. Furthermore, endoscopic ablation of NDBE was not
routinely performed in the Netherlands during the study
period, which minimizes the risk of a change of the
natural history of BE due to treatment. Additionally,
adding treated LGD as an outcome did not signiﬁcantly
change the results.
Some limitations warrant consideration as well. First,
no clinical and endoscopic data were available, and de-
tails regarding the indication and the number of biopsies
are not uniformly registered. Therefore, progression
risks could not be adjusted for known risk factors, such
as length of the BE segment, presence of esophagitis, and
use of medication.22 Endoscopic conﬁrmation is essential
for a diagnosis of BE. Intestinal metaplasia on biopsy
without being present on endoscopy could underesti-
mate the malignant progression rate.23 Our veriﬁcation
cohort suggests that only 10% of patients had a BE
segment <1 cm. Furthermore, the sensitivity analysis
showed that the possible inclusion of patients without
endoscopic evidence of BE has only a minimal effect on
the overall conclusions. Hence, the 10% rate we detected
in the validation substudy (if extrapolated to the total
population) is probably not important, as only a rate
above 25% will impact the results. Second, in this study
14,088 NDBE patients did not undergo histologic follow-
up. Older age, comorbidities, and misdiagnosis of BE (as
patients with BE <1 cm are currently excluded from
endoscopic surveillance) could possibly be an
explanation.5 As this group was relatively large, the
actual progression risk might be even lower if symp-
tomatic patients had undergone endoscopy more
frequently. Third, there was a lack of central pathology
review. However, contrary to dysplasia, both the repro-
ducibility of intestinal metaplasia and the accuracy of
diagnostic codes for BE are high.24 Furthermore, addi-
tional immunohistochemistry, such as p53 staining and
Alcian blue stain, was not performed on a routine basis.22
Finally, all patients had varying periods of follow-up. We
therefore presented the results of this study as events
per 100 person-years of follow-up. The study was not
designed to deﬁnitively answer questions concerning
how long or how frequently patients with persistent
NDBE should remain in surveillance. Further risk strat-
iﬁcation is needed to conclusively identify patients in
which surveillance can safely be discontinued.
In conclusion, this population-based analysis dem-
onstrates a very low incidence of HGD or EAC among
patients with NDBE. The risk decreases further after
consecutive negative endoscopies performed at least 1
year apart. Persistent NDBE may be a useful risk strati-
ﬁcation tool for future surveillance programs. Our ﬁnd-
ings suggest that lengthening of the surveillance
intervals could be considered in a subgroup of patients
with 3 or more surveillance endoscopies showing NDBE,
and contribute to the growing evidence that there may
be an endpoint for routine surveillance in patients with
persistent NDBE. However, discontinuing surveillance
should be considered with caution in patients with
symptoms or with previous endoscopic ﬁndings that are
suspicious for neoplasia development.
Supplementary Material
Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
Gastroenterology and Hepatology at www.cghjournal.org,
and at https://doi.org/10.1016/j.cgh.2018.08.033.
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Supplementary Methods
Endoscopic conﬁrmation is essential for a diagnosis
of Barrett’s esophagus (BE), intestinal metaplasia on bi-
opsy without being endoscopically presented, could un-
derestimate the malignant progression rate. In a
sensitivity analysis, we assessed the effect of misclassi-
ﬁcation of BE on the progression rates toward high-grade
dysplasia or esophageal adenocarcinoma. Patients with
BE <1 cm likely have a negligible risk of malignant
progression. Hence, the possible inclusion of patients
with BE <1 cm will increase the total follow-up time,
thereby decreasing the malignant progression rate.
Based on our veriﬁcation cohort, the total follow-up time
will decrease with 2.91 years (ie, median follow-up)
multiplied by the number of misclassiﬁed patients. Sub-
sequently, we estimated incidence rates of high-grade
dysplasia or esophageal adenocarcinoma for different
rates of misclassiﬁcation of BE.
We performed a similar analysis in patients with
persistent nondysplastic Barrett’s esophagus at 2
consecutive endoscopies.
Supplementary Figure 1. Incidence rates of esophageal
adenocarcinoma (EAC) and the combined endpoint of high-
grade dysplasia (HGD) and EAC based on calendar year of
initial nondysplastic Barrett’s esophagus (NDBE) diagnosis.
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Supplementary Figure 2. (A) Estimate of the change in incidence rates of high-grade dysplasia (HGD) and esophageal
adenocarcinoma (EAC) based on the percentage of patients misclassiﬁed as Barrett’s esophagus (BE). Only a misclassiﬁcation
rate of more than 25% will signiﬁcantly inﬂuence the HGD or EAC incidence rate (P ¼ .02). (B) Estimate of the change in
incidence rates of HGD and EAC in patients with persistent nondysplastic BE at 2 consecutive endoscopies based on the
percentage patients misclassiﬁed as BE at initial endoscopy. The inclusion of patients without BE at initial endoscopy did not
signiﬁcantly change the HGD or EAC incidence rates (P ¼ .67).
Supplementary Table 1. Search Strategy, PALGA Diagnostic Codes, and Words Used in Analysis
Variable PALGA Codes Words in Pathology Conclusion
Esophagus T62000, T62010 Slokdarm, oesofagus, esophagus
Barrett’s esophagus T62. þ M73320 /
T62310M73330 Intestinal metaplasia, distinctive type, specialized type
Indeﬁnite for dysplasia No diagnostic codes Indeﬁnite, undetermined, correction for misspellings.
Low-grade dysplasia M74000, M74006, M74007 Laaggradige dysplasie, low grade dysplasia, geringe dysplasie,
lichte dysplasie, matige dysplasie
High-grade dysplasia M74008, M81402 Hooggradige dysplasie, high grade dysplasia, ernstige dysplasie,
sterke dysplasie, adenocarcinoom in situ
Esophageal
adenocarcinoma
M80003, M80011, M80101, M80103,
M80105, M81403, M81453, M84803,
M81443
Adenocarcinoom,
Intramucosaal carcinoom,
Gedifferentieerd carcinoom
PALGA terminology: http://www.palga.nl/palga/thesaurus.nsf.
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Supplementary Table 2. Baseline Characteristics and Risk of Progression to EAC and HGD or EAC Combined of Patients Included and Excluded From This Study
Included Patients Excluded Patients
Total Cohort
(n ¼ 12,728)
Progression to HGD/EAC
Within 1 Year of Follow-Up
(n ¼ 116) P Value
Atypia during initial
NDBE diagnosis
(n ¼ 555) P Value
FU Endoscopies Without
Esophageal Biopsy
Sampling (n ¼ 750) P Value
Patients Without
Follow-Up
(n ¼ 13,338) P Value
Sex .002 .456 <.001 <.001
- Male 8673 (68.1) 95 (81.9) 370 (66.7) 408 (54.4) 8363 (62.7)
- Female 4055 (31.9) 21 (18.1) 185 (33.3) 342 (45.6) 4975 (37.3)
Age, y 57.9  11.5 67.0  12.4 <.001 59.08  11.53 .017 61.29  12.60 <.001 64.6  14.1 <.001
Follow-up, y 4.4 (3.0–6.7) 0.2 (0.1–0.5) <.001 4.6 (3.0–7.3) .19 0 <.001
EAC
Progression to EAC 304 (2.4) 91 (78) <.001 26 (4.7) .002 NA NA
EAC incidence rate/100 PY
(95% CI)
0.47 (0.42–0.53) NA 0.88 (0.59–1.27) .006 NA NA
Time to EAC diagnosis, y 5.1 (3.3–7.3) 0.17 (0.06–0.50) <.001 3.99 (2.51–5.31) .068 NA NA
HGD/EAC
Progression to HGD/EAC 436 (3.5) 116 (100) <.001 33 (5.9) .002 NA NA
HGD/EAC incidence rate/100
PY (95% CI)
0.68 (0.61–0.74) NA 1.13 (0.78–1.56) .016 NA NA
Time to HGD/EAC diagnosis, y 4.9 (3.2–7.3) 0.19 (0.07–0.41) <.001 4.15 (2.91–5.24) .077 NA NA
NOTE. Values are n (%), mean  SD, or median (interquartile range), unless otherwise indicated.
CI, conﬁdence interval; EAC, esophageal adenocarcinoma; FU, follow-up; HGD, high-grade dysplasia; NDBE, nondysplastic Barrett’s esophagus; PY, patient-years.
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Supplementary Table 3. Dysplasia Cases Conﬁrmed by a Second Pathologist Q5
Variable IND n ¼ 510 LGD n ¼ 977 HGD n ¼ 170
External revisiona 101 (19.8) 191 (19.5) 95 (55.9)
Internal revisionb 230 (45.1) 409 (41.9) 56 (32.9)
No revision, persistent dysplasia, or progression to LGD/HGD/EAC 34 (6.7) 81 (8.3) 12 (7.1)
No revision 145 (28.4) 268 (27.4) 7 (4.1)
NOTE. Values are n (%).
EAC, esophageal adenocarcinoma; HGD, high-grade dysplasia; IND, indeﬁnite for dysplasia.
aExternal revision was deﬁned as present if a second expert pathologist in an expert center conﬁrmed the diagnosis.
bInternal revision was deﬁned as present if a second pathologist conﬁrmed the diagnosis.
Supplementary Table 4. Location and Presence of Surgical or Endoscopic Resection Specimens of the 304 Detected
Adenocarcinomas
Location
Final Diagnosis Made by
Biopsy EMR Surgical Resection
Esophagus (n ¼ 292) 101 (34.6) 120 (41.1) 71 (24.3)
GE junction or cardia (n ¼ 6) 4 (66.7) 0 (0.0) 2 (33.3)
Unknown (n ¼ 6) 6 (100) 0 (0.0) 0 (0.0)
NOTE. Values are n (%).
EMR, endoscopic mucosal resection; GE, gastroesophageal.
FLA 5.5.0 DTD  YJCGH56023_proof  23 November 2018  4:02 pm  ce OB
- 2018 Low Cancer Risk in Persistent NDBE 9.e4
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
Supplementary Table 5.Group Characteristics and Risk of Progression to EAC and HGD or EAC Based on the Number of
Consecutive Endoscopies Showing NDBE
Variable
Consecutive Upper Endoscopies Showing NDBE
1 n ¼ 12,728 2 n ¼ 6278 3 n ¼ 2677 4 n ¼ 1051 5 n ¼ 378
Male 8673 (68.1) 4359 (69.4) 1861 (69.5) 751 (72.7 ) 277 (73.3)
Age, y 57.9  11.5 58.8  11.0 59.7  10.7 60.7  10.7 60.7  10.3
Time to nth FU endoscopy, y 0.0 (0.0–0.0) 2.0 (1.2–2.8) 4.0 (3.0–5.0) 5.8 (4.3–6.6) 6.9 (5.1–8.1)
FU after n endoscopies, y 4.4 (3.0–6.7) 3.7 (2.7–6.0) 3.3 (2.4–5.2) 3.1 (2.3–4.4) 2.4 (2.1–3.9)
EAC
Development of EAC 304 (2.4) 101 (1.6) 38 (1.4) 18 (1.7) 5 (1.3)
EAC incidence rate/100 PY (95% CI) 0.47 (0.42–0.53) 0.37 (0.30–0.44) 0.36 (0.26–0.49) 0.49 (0.30–0.75) 0.42 (0.16–0.94)
Adjusted incidence rate ratio (95% CI)a,b 1.00 (reference) 0.69 (0.55–0.87) 0.62 (0.44–0.86) 0.74 (0.46–1.20) 0.60 (0.25–1.45)
HGD/EAC
Development of HGD/EAC 436 (3.5) 150 (2.4) 57 (2.1) 25 (2.4) 9 (2.4)
HGD/EAC incidence rate/100 PY (95% CI) 0.68 (0.61–0.74) 0.55 (0.46–0.64) 0.54 (0.41–0.69) 0.67 (0.45–0.98) 0.76 (0.37–1.40)
Adjusted incidence rate ratio (95% CI)a,b 1.00 (reference) 0.72 (0.60–0.87) 0.65 (0.49–0.86) 0.73 (0.49–1.09) 0.76 (0.39–1.47)
NOTE. Values are n (%), mean  SD, or median (interquartile range), unless otherwise indicated.
EAC, esophageal adenocarcinoma; FU, follow-up; HGD, high-grade dysplasia; NDBE, nondysplastic Barrett’s esophagus; PY, patient-years.
aPoisson regression used to calculate incidence rate ratio using the ﬁrst upper endoscopy as the reference group.
bPoisson model adjusted for gender and age at nth FU endoscopy.
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